Sökning: id:"swepub:oai:DiVA.org:oru-93451" >
Discordance of PD-L...
-
Boman, CarolineKarolinska Institutet
(författare)
Discordance of PD-L1 status between primary and metastatic breast cancer : A systematic review and meta-analysis
- Artikel/kapitelEngelska2021
Förlag, utgivningsår, omfång ...
-
Elsevier,2021
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:oru-93451
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-93451URI
-
https://doi.org/10.1016/j.ctrv.2021.102257DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:147536725URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:for swepub-publicationtype
Anmärkningar
-
INTRODUCTION: Programmed cell death ligand 1 (PD-L1) expression is predictive for benefit from immunotherapy in several human malignancies including triple negative breast cancer. Lower positivity rates but a larger relative benefit from atezolizumab has been implied when PD-L1 status is assessed at metastatic sites. We aimed to study the discordance of PD-L1 expression between primary tumor and metastasis in breast cancer due to its potential clinical utility.METHODS: Cochrane Library, Embase, Medline and Web of science were searched for studies reporting on PD-L1 expression in primary and metastatic breast cancer, followed by data extraction. Outcomes included pooled PD-L1 positivity rates in tumor cells, immune cells or both in primary tumor and metastasis, PD-L1 discordance between matched primary tumors and metastasis and direction of discordance.RESULTS: Of 2552 identified entries following de-duplication, 20 studies fulfilled the predefined inclusion criteria. Pooled PD-L1 positivity rate was higher in primary tumors compared to metastasis when assessed in immune cells (51.2% vs 37.1% p < 0.001) and tumor/immune cells (30.1% vs 14.6% p < 0.001), but not in tumor cells (18.7% vs 17.8% p = 0.65). PD-L1 positivity was lowest when assessed in bone metastases (12%) and highest in lymph nodes (60%). Discordance between primary tumors and metastasis was bidirectional, with higher pooled discordance rates when PD-L1 expression was assessed in immune compared to tumor cells (39.5% vs 13.6%, p < 0.001).CONCLUSION: The observed considerable discordance between PD-L1 status in primary and metastatic breast cancer emphasizes the importance of appropriate tissue sampling when selecting patients for immunotherapy.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Zerdes, IoannisKarolinska Institutet
(författare)
-
Mårtensson, KiraDepartment of Clinical Pathology and Cytology, Karolinska University Laboratory, Stockholm, Sweden
(författare)
-
Bergh, JonasKarolinska Institutet
(författare)
-
Foukakis, TheodorosKarolinska Institutet
(författare)
-
Valachis, Antonis,1984-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology(Swepub:oru)asvs
(författare)
-
Matikas, AlexiosKarolinska Institutet
(författare)
-
Karolinska InstitutetDepartment of Clinical Pathology and Cytology, Karolinska University Laboratory, Stockholm, Sweden
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Cancer Treatment Reviews: Elsevier990305-73721532-1967
Internetlänk
Hitta via bibliotek
Till lärosätets databas